Understanding the role of hypoxia inducible factors in liver fibrosis and future therapeutic applications Authors: Yasha Taimuri, Riaz Ahmad Published: 2026 ABSTRACT AbstractLiver fibrosis is a chronic and progressive outcome of liver injury and continues to be a major contributor to liver morbidity and mortality. It is characterized by the excessive accumulation of extracellular matrix, resulting in the loss of normal liver architecture. Chronic liver injury also affects the availability of oxygen in the liver tissue, resulting in a hypoxic microenvironment. Among the major mediators of the hypoxic response, hypoxia-inducible factor-1α (HIF-1α) has been identified as a major regulator of fibrogenesis. The major experimental and clinical data have shown that the HIF pathway is closely linked to the activation of hepatic stellate cells, inflammation, pathological angiogenesis, and metabolic derangements in the fibrotic liver. These events are interlinked and result in the promotion of ongoing matrix accumulation and tissue remodeling. Recent studies have also indicated that the hypoxic pathways may cross-talk with ferroptosis and iron-mediated oxidative damage, providing new information on the mechanisms underlying the progression of fibrosis. This review aims to provide an overview of the current evidence on the role of HIF-1α in liver fibrosis and its connection between the major profibrotic pathways. We also provide information on the new therapeutic approaches targeting hypoxia signaling, including pharmacological inhibitors, von hippel-lindau (VHL) pathway modulation, and naturally derived compounds that have been reported to possess antifibrotic activity. A better understanding of the mechanisms driven by hypoxia may provide new information for the development of more accurate and stage-specific therapies for chronic liver diseases.Keywords: Liver fibrosis, HIF-1α, Hypoxia, Hepatic stellate cells, Angiogenesis Introduction Liver fibrosis: an overview Chronic liver disease (CLD) is a long-term illness of the liver. It is a significant health problem globally, being the 11th leading cause of death and 14th leading cause of disability.1 Hepatic fibrosis, a pathologic feature appearing upon chronic liver diseases, is an early sign of hepatocarcinoma in chronic liver diseases like viral hepatitis and non-alcoholic fatty liver disease. Although liver biopsy represents the gold standard for the diagnosis, non-invasive imaging techniques have become more practical and are widely used. Three stages are involved in fibrosis in the response to injury of the liver, which leads to stellate cell activation, fibroblast proliferation, and extracellular matrix deposition, causing degradation of liver architecture, loss in hepatic function, and increased portal pressure. This pathway can lead to cirrhosis, liver failure, portal hypertension, and hepatocarcinoma.2 Liver fibrosis is a complex fibro-inflammatory disorder characterized by an excessive synthesis of the extracellular matrix and has a multifactorial etiology involving lifestyle, environmental, genetic, and epigenetic factors that affects over 100 million patients worldwide. In this context, angiogenesis or the process of new blood vessel formation, is a key step in the progression of hepatocellular carcinoma (HCC).3 Liver diseases cause roughly 1.5–2.0 million deaths yearly and remain a major global health burden driven by viral hepatitis, alcohol, and the rapidly rising incidence of fatty liver disease related to metabolism. Patterns differ by region: viral causes falling in some areas, while non-alcoholic fatty liver disease (NAFLD) and alcohol-related disease rise, with projected increases in cirrhosis and NAFLD-related cases.4 The alarming lifestyle choices of people have led to preferences for a Western diet, a sedentary lifestyle, and increased alcoholism. The liver is an organ in proximity to blood circulation in the human body, unique in that it receives blood from multiple arteries in the body. Hence, it gets directly in contact with multiple extrinsic factors, including dietary metabolites and gut-absorbed compounds, including drugs or alcohol. These agents can cause liver injury or lead to fibrogenesis. Chronic liver injury may progress to liver fibrosis and eventually to cirrhosis or hepatocellular carcinoma (HCC). Hepatic stellate cells (HSCs) are considered to play a dynamic role and transdifferentiate into myofibroblast-like cells which are regarded as the major ECM-producing cells during liver fibrosis.5,6 Inflamed liver tissue has activated quiescent hepatic stellate cells and other precursors to drive myofibroblast transformation to produce extracellular matrix, driven by pro-fibrogenic mediators such as chemokines, interleukins, and growth factors, secreted by multiple liver-resident cells. About hypoxia-inducible factors (HIFs) The von hippel-lindau (VHL) gene is a tumour suppressor gene that encodes a protein, termed the VHL protein. HIFs belong to the basic helix-loop-helix-Per-Arnt-Sim (Bhlh-PAS) transcription factor superfamily.7 In hypoxic conditions, there is an increased expression of vascular endothelial growth factor (VEGF).8 Thus, hypoxia-inducible; HIF-1α and HIF-1β are two key subunits of hypoxia-inducible factor-1. The primary regulatory subunit for oxygen is HIF-1α, while HIF-1β, also known as aryl hydrocarbon nuclear translocator (ARNT), is seen as a common subunit for different transcription factors.7 Under normal oxygen conditions, HIF-1α is degraded in the cytoplasm with a half-life of less than 5 min 9. This is followed by ubiquitination and subsequent proteasomal degradation of HIF-1α. Under hypoxic conditions, this process is blocked, and HIF-1α translocates to the nucleus10 (Fig. 1). The oxygen-dependent regulation of HIF-1α process is also illustrated in Fig. 1. Under hypoxic conditions, HIF-1α escapes degradation and translocates to the nucleus, whereas under normoxic conditions, VHL-mediated ubiquitination targets HIF-1α for proteasomal degradation, in which a family of prolyl hydroxylase domain (PHD) enzymes, PHD1, PHD2, and PHD3, hydroxylate HIF-1α. Later, HIF-1α is then conjugated to an E3 ubiquitin ligase complex containing VHL protein, which induces degradation of HIF-1α. Regulation of HIF-1α under hypoxic and normoxic conditions. (A) Under hypoxic conditions, the lack of oxygen inhibits prolyl hydroxylase activity, preventing hydroxylation and degradation of HIF-1α. Stabilized HIF-1α accumulates in the cytoplasm, translocates to the nucleus, dimerizes with aryl hydrocarbon receptor nuclear translocator (ARNT), and activates transcription of hypoxia-responsive genes. (B) Under normoxic conditions, HIF-1α undergoes prolyl hydroxylation by prolyl hydroxylase enzymes, enabling recognition by the von Hippel–Lindau (VHL) protein. VHL-mediated ubiquitination targets HIF-1α for proteasomal degradation, thereby preventing activation of hypoxia-responsive gene expression. Abbreviations: ARNT, aryl hydrocarbon receptor nuclear translocator; HIF-1α, hypoxia-inducible factor-1α; Ub, ubiquitin; VHL, von hippel-lindau protein. HIF in the development of liver diseases The liver has major functions of detoxifying toxic metabolic products, synthesising several proteins and clotting factors, and excreting bile. It is a constitutive, compelling reaction by the liver through inflammation, destructive and regulatory functions of the liver parenchyma, leading towards fibrosis and cirrhosis. Cirrhosis is the final stage of CLDs, characterized by distortion of normal liver architecture, generation of widespread nodules, vascular remodeling, neo-angiogenesis, and ECM deposition. Mechanistically, at the cellular level, hepatic stellate cells and fibroblasts are recruited, leading to fibrosis. Cytokines are small glycosylated proteins that act as key regulators of immune and inflammatory responses. They are secreted by multiple cell types, including lymphocytes and leukocytes, and are involved in a wide range of normal as well as disease processes.11 In this review, we discuss several pathways by which cytokines promote liver fibrosis in an HIF-dependent manner. Cholestasis is an impairment of bile flow causing toxic bile accumulation and liver injury, whereas metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD, is characterized by hepatocellular lipid accumulation driven by metabolic, inflammatory, and oxidative hits. Bile acids and their receptors (FXR/TGR5) functionally link both disorders and are the focus of central therapeutic and biomarker advances12. MASLD is strongly tied to obesity, diabetes, and dyslipidemia. MASH is a progressive subset of MASLD characterized by fat accumulation, inflammation, and liver damage that may progress to fibrosis, cirrhosis, and hepatocellular carcinoma. Compared to simple steatosis, which might be regarded as mild and reversible, it is recognized as more serious and irreversible.13 Oxidative stress results from a mismatch between the production and accumulation of reactive oxygen species (ROS) in cells and tissues and the body's ability to detoxify these reactive species.14 Vaupel and colleagues (2007) stated periportal pO2 ≈ 45–65 mmHg and perivenous pO2 ≈ 15–25 mmHg in a healthy liver, while reviews of the HCC report intratumoral pO2 falling to about 6 mmHg. Hypoxia acts as a critical molecular bridge connecting initial liver injury to HCC Chronic viral infection or steatosis-related inflammation leads to hypoxia, which exacerbates with liver injury, fibrosis, cirrhosis, and HCC progression, as dysfunctional vasculature reduces O2 delivery and generates hypoxic microenvironment.15 The significance of HIFs in the development and progression of liver fibrosis is summarised in this review. This section explains the molecular biology and control of the HIF signaling pathway, with an emphasis on mechanisms regulating HIF activation in the context of hypoxia. The review also examines the function of HIFs in activation of hepatic stellate cells, angiogenesis, inflammation, metabolic reprogramming, ferroptosis in fibrogenesis, and new therapeutic options targeting HIF signaling like pharmacological inhibitors, epigenetic modulators, phytomedicines and von hippel-lindau (VHL)-based therapies. Finally, the review critically analyses the translational potential, existing limits and future perspectives of HIF-targeted treatments for liver fibrosis. Methodology Data sources and literature search strategy A detailed literature search was conducted using the PubMed, Scopus, Web of Science, and ScienceDirect databases for papers relevant to HIFs and hepatic fibrosis. The final reference list included works published from 1985 to 2025, from the dawn of discoveries to contemporary developments in the discipline. Search terms were combinations of “HIF-1α”, “HIF-2α”, “hypoxia”, “liver fibrosis”, “hepatic stellate cells”, “angiogenesis”, “ferroptosis”, “von hippel–lindau (VHL)”, “phytochemicals”, and “antifibrotic therapy”. We considered studies that, (1) investigated the role of HIF signaling in liver fibrosis or related chronic liver illnesses, (2) investigated molecular processes underlying hypoxia-mediated fibrogenesis, or (3) evaluated treatment methods targeting HIF-associated pathways. Studies not directly connected to liver fibrosis, conference papers, editorials, duplicate records and articles with insufficient mechanistic information were excluded. The process of the literature selection is summarised in a PRISMA-style flow diagram (Fig. 2). Database searching identified a total of 345 records; 87 duplicate records were deleted before screening. Remaining records (258) were considered and screened and, 96 records were excluded as they were irrelevant. 162 reports were reviewed for eligibility after title and abstract screening. Studies not focused on hepatic fibrosis (n = 18), editorials or conference abstracts (n = 7), lacking mechanistic information (n = 6) or judged redundant (n = 6) were omitted. Finally, 125 studies fulfilling the established inclusion criteria were included in the final review. Given the narrative structure of this evaluation, a formal risk-of-bias assessment was not conducted. However, the focus was on peer-reviewed original research publications, systematic reviews, and studies having significant mechanistic, translational, and therapeutic relevance to HIF signaling and liver fibrosis. Procedure of systematic collection of data. Hypoxic regions in liver injury In fact, hypoxic regions in the liver are critical to understand liver damage as they are primarily over-represented in numerous liver pathologies. Hypoxia, or low levels of oxygen, can cause zone-specific injury to the liver, affecting the periportal (zone 1) and pericentral (zone 3) areas of the liver lobule. Its damaging effects are modulated by things like nutritional state and the up-regulation of hypoxia-inducible factors (HIFs), which regulate the expression of genes and metabolic processes in low oxygen environments. Liver damage induced by hypoxia is zone-dependent and more pronounced in the pericentral region than the periportal region. This damage was worsened by hypoxia resulting from ischemia or low blood flow, and its severity increased when reflow was applied in perfused rat liver preparations; this effect was both rapid and extensive, especially in fasted rats. In agreement with this, the pericentral area took up more dye and thus incurred more damage than the periportal region.16 Hypoxia regulates gene expression in liver cells; specifically, HIF-1 acts as a repressor of genes, including α-fetoprotein (AFP) in hepatoma cells. This repression occurs through a particular hypoxia response element, suggesting a complex regulatory interplay where HIF-1 and c-Myc might antagonise each other in regulating gene expression in response to hypoxia. HIF-dependent metabolic reprogramming has been implicated in hypoxia-mediated drug resistance in hepatocellular cancer, emphasising the necessity of hypoxia-targeted therapies to improve treatment efficacy.17 Hypoxia is a key contributor to liver injury but also plays an important part in adaptive responses that may be protective under certain situations. Studies on polyunsaturated fatty acid (PUFA) metabolism in the liver have shown its destructive and adaptive mechanisms contributing to diverse liver diseases, and the balance between these processes is anticipated to be key for therapeutic methods to limit liver injury and improve liver health. Substances like monocrotaline18 or acetaminophen cause injury to the liver, leading to the formation of hypoxic zones. Pimonidazole, a hydroxyprobe, has been used to confirm the presence of hypoxic regions.19 Indeed, HIF-1α is currently recognized to be one of the only unambiguous markers of hypoxia in the livers of mice treated with ethanol, carbon tetrachloride and acetaminophen.9 In summary, HIF-1α serves as the primary cellular oxygen sensor and plays a central role in coordinating transcriptional responses to hypoxia, thereby influencing multiple processes relevant to liver fibrosis. Hepatic stellate cells (HSCs) and collagen synthesis Friedman et al. showed that HSCs were the primary cells responsible for collagen production in the liver.5 Enhanced liver regeneration may avoid liver fibrosis and injury, and hypoxia increases collagen synthesis in HSCs.20 Obesity and changes in intestinal HIF-1α can trigger a progression of liver damage that may eventually lead to liver cirrhosis. HIF-1α also plays a crucial role in NAFLD and mediate cellular responses to oxygen depletion in the liver.21 The hypoxia-exposed mouse HSCs showed overexpression of genes including CCR1, CCR5 and VEGF-A in an HIF-1α-dependent manner. HIF-1α and HIF-2α induce de novo lipogenesis (DNL) and fatty acid uptake, linking hypoxia to NAFLD.22 Fibrosis-induced hypoxia stimulates hepatic stellate cells (HSCs) to increase the production of α-SMA, HIF-1α, and IL-6, thereby promoting liver fibrosis. This results in elevated IL-6 production, which is diminished by inhibition of HIF-1α or knockdown of HIF1A, as HIF-1α directly interacts with the HRE area in the IL6 promoters. Expression of HIF-1α in HSCs increases IL-17 A in naïve CD4 T cells, which also acts to induce IL-6 in HSCs, suggesting feedback. This suggests that HIF-1A indirectly regulates the immune response and fibrosis through interactions between IL-6 and IL-17 A.23 Mice deficient in HIF-1α develop reduced fibrosis.24 Under chronic hypoxia, following changes were encountered in mouse hepatocytes: enhanced polymerization of F-actin; augmented markers of increased mesenchymal cell content (α-SMA, vimentin); increased epithelial-mesenchymal transition mediators (FSP, snail-1) and reduced epithelial proteins (zona occludins, E-cadherin).24 The findings also provide evidence that chronic AKG administration may be beneficial in treating cadmium-induced liver injury and inflammation. AKG alleviates oxidative stress and inflammation in hepatocytes by the degradation of HIF1A and preventing the inhibition of TNFAIP3.25 HIF-mediated angiogenic signaling in liver fibrosis VEGF is a critical factor for the formation of new blood vessels (angiogenesis), which is driven by factors such as hypoxia and oncogenes. In liver fibrosis, VEGF is secreted by various cells, including hepatic stellate cells, hepatocytes, and sinusoidal endothelial cells. It drives disease progression by promoting pathological angiogenesis and regulating HSC activation, the primary drivers of collagenesis in the liver. VEGF levels increase in activated HSCs, and its levels are shown to be downregulated in collagen and ECM accumulation in particular mice models. HIF-1α binds in proximity to the VEGF promoter to induce VEGF gene expression, and has been shown to synergize with other genes to amplify VEGF activity. As with other mediators such as STAT3, HIF-1α directly regulates VEGF transcription in hepatic cells,26 hence lining up VEGF as a putative target gene for HIF-1α. VEGF may modulate HIF-1α itself; i.e., in transgenic mice models, elevated levels of VEGF-A led to a decrease in HIF-1α and fibrosis. Moreover, PI3K/AKT and mitogen-activated protein kinase (MAPK) pathways mediate VEGF signaling, involved in HIF-1α activity regulation.27 VEGF delivery further stimulates liver regeneration after partial hepatectomy in rats.28 In human peritoneal cells, dermal fibroblasts and cardiac fibroblasts, hypoxia induces the expression of collagen I and III.29 Under hypoxic conditions, HSCs also upregulate the production of collagen α1 (I), which alters ECM composition, leading to liver fibrosis.20 Liver fibrosis was marked by upregulation of chemokine receptors (CCR1, CCR5), prolyl 4-hydroxylases (α1, α2), and proangiogenic mediators such as placental growth factor and Angiopoietin-like 4 (Fig. 3). Most of these genes had HIF-1-dependent upregulation in HSCs and are suggestively active in liver fibrogenesis.30 We have conceived the central role of HIF-1α in coordinating hepatic stellate cell activation, inflammatory signaling, angiogenesis, and extracellular matrix deposition during liver fibrogenesis (Fig. 3). Hypoxia-driven HIF-1α signaling orchestrates hepatic stellate cell activation, angiogenesis, inflammation, and extracellular matrix remodeling during liver fibrogenesis. Pericentral hypoxia stabilizes HIF-1α in the liver, leading to activation of hepatic stellate cells (HSCs) and upregulation of profibrogenic (α-SMA, COL1), inflammatory (IL-6, CCR1/CCR5), angiogenic (VEGF, ANG1, VEGFR2, TIE2), and matrix-remodeling (MMPs) pathways. These coordinated responses promote extracellular matrix deposition, pathological angiogenesis, and liver inflammation, ultimately driving fibrosis. Genetic ablation of HIF-1α attenuates downstream signaling and suppresses fibrogenic progression. Abbreviations: Ang1, angiopoietin-1; CCR1, C-C chemokine receptor 1; COL1, collagen type I; ECM, extracellular matrix; FGF2, fibroblast growth factor 2; HIF-1α, hypoxia-inducible factor-1α; HSC, hepatic stellate cells; IL-6, interleukin-6; MMP, matrix metalloproteinase; α-SMA, alpha-smooth muscle actin; PAI1, plasminogen activator inhibitor-1; PDGF, platelet-derived growth factor; Tie2, tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2. Hypoxic regions are associated with elevated microvessel density, fibrous septa, and inflammation, cascading towards angiogenesis and fibrosis. Hypoxia, angiogenesis, chronic inflammation, and fibrosis create a positive feedback loop in the injured liver, and severe liver fibrosis is induced by synergistic interactions between these systems. PDGF-B produced by endothelial cells/liver sinusoidal endothelial cells (ECs/LSECs) promotes vessel stabilisation through PDGFR recruitment, emphasising the importance of HSCs in linking inflammation, fibrosis and angiogenesis.31 Neovascularization driven by VEGF pathways accelerates liver fibrosis progression; anti-angiogenic therapies show promise in reducing hepatic damage and cirrhosis by targeting pathological angiogenesis. Hepatic stellate cells demonstrate pro-angiogenic abilities through the activity of HIF-1α pathways in response to hypoxia, leading to the production of VEGF, Ang-1 and their respective receptors VEGFR-2 and Tie-2 (Fig. 3.).32 In fact, HSCs promote angiogenesis regardless of hypoxic conditions through their activation by pro-fibrogenic mediators such as PDGF and leptin that shape vascular dynamics and stimulate the expression of angiogenic factors including VEGF and Ang-1.33 Because liver steatosis promotes hypoxic conditions, the perivenous area is most affected by these processes. Mitochondrial injury occurs due to increased oxygen demand from high fatty acid metabolism activity, whereas sinusoidal compression and HSC contraction impairs oxygen delivery due to steatosis and fibrosis. Hypoxia-inducible factors stimulate the process of angiogenesis during hypoxia and LSECs, which have no basement membrane and fenestrae, can transport macromolecules across sinusoids. The occurrence of intermittent hypoxia due to obstructive sleep apnea syndrome (OSAS) elevates NAFLD risk, regardless of other determinants.34 The process of pathological angiogenesis, which is associated with liver fibrosis and mediated by pro-angiogenic factors released from hypoxic hepatocytes and hepatic stellate cells, has been documented in multiple NASH animal models, and is most apparent in perisinusoidal areas, particularly zone-3, of patients and rats with NASH.35 Collectively, HIF-mediated angiogenic signaling promotes pathological vascular remodeling and contributes significantly to the progression of liver fibrosis. Effect of HIF-induced cytokines on liver fibrosis Hypoxia and inflammation Hypoxia is involved in inflammation during liver injury and is also an activator of Nuclear-factor kappa B (NF-κB). HIF-1α protein accumulation is dependent on the activity of NF-κB and IKKB (inhibitor of nuclear factor kappa B kinase − β and γ) in the liver of hypoxia-induced animals and macrophages, respectively. The hypoxic response is associated with innate immunity and inflammation.36 Published evidence showed that a two-hit hypothesis has been developed in which fat accumulation in liver and associated oxidative stress and inflammation are required for steatohepatitis; and both insults are HIF-2α dependent.37 IL-6 is a profibrogenic and proinflammatory cytokine that induces HSC proliferation and α-SMA expression through the p38 MAPK signaling pathway.38 TGF-β is a multifunctional cytokine involved in homeostasis and immune regulation, while aberrant signaling is associated with cancer initiation, fibrosis, EMT, invasion, metastasis, and angiogenesis occurring in a hypoxic state.39 PDGF-B is implicated as an important mediator of inflammation and fibrogenesis in liver injury. Copple and co-workers have reported that macrophages make significant contributions to liver fibrosis through the release of important mediators, including PDGF-B and TGF-β1, inducing proliferation, chemotaxis, and collagen synthesis in HSCs. HIF-1α or HIF-1β knockout mice showed less expression of α-SMA and type-1 collagen. PDGF-β production by macrophages following HIF activation leads to the advancement of fibrosis.40 Thus, HIF-1β or HIF-1α deletion on macrophages and neutrophils will likely lead to fibrosis regression, especially post-BDL.41 After inhibition of PDGF signaling, it was reported that fibrosis decreased after BDL. Together, these findings indicate that HIF-1α is a potent regulator of PDGF-β in liver fibrosis progression. The upregulation of PDGF-β in vitro was also shown to occur in a HIF-1α-dependent manner in hypoxic Kupffer cells.42 Together, the findings provide evidence for the contribution of Kupffer cells and HIF-1α to fibrosis, with PDGF-B functioning as an integral pro-fibrotic factor involved in HSC activation and fibrogenesis. Hypoxic hepatocytes activate latent TGF-β1 through an HIF-dependent mechanism, which promotes PAI-1, VEGF, and other fibrogenic pathways.42 Under hypoxia, both HIF-1α and HIF-2α are activated, resulting in such increases of prolyl-4-hydroxylase α1 and α2 that can stabilise collagen's triple helices.40 Col mRNA transcripts and HIF-related determinants—SMA (smooth muscle actin) under hypoxic conditions were elevated, and HIF-2α deletion blocked collagen progression/fibrosis. Data from high-fat diet-induced mice shows that PDTC, an inhibitor of NF-κB, reduces fibrosis through the ultimate blockade of NF-κB. In NASH liver, prolonged hypoxia and a high-fat diet led to increased concentrations of HIF-2α and NF-κB, pointing to a mechanistic link between hypoxia and the development of fibrosis.43 Therapy of HIF/PTEN has also been implicated in alleviating diet-induced liver fibrosis. Hypoxia is involved in important phenomena that characterise several models of liver fibrosis.20,24 Role of HIF-1α and oxidative stress in fibrosis In models of liver disease like alpha-1-antitrypsin deficiency, oxidant stress is known to promote liver damage and progression of fibrosis, reinforcing its role in fibrogenesis.44 HIF-1α participates in regulating oxidative stress responses in HSCs. Depending on context, it modulates pathways that can promote or inhibit fibrosis. Much of this is dependent upon the presence of signaling pathways; for example, in HSCs the HIF-1α/SLC7A11 pathway plays an important regulatory role in the cell death procedure and as a critical switch for ferroptosis. Targeted inhibition of this pathway via sorafenib leads to diminished hepatic stellate cell activation and to reduces fibrosis.45 Toxin-induced oxidative stress has been implicated in liver injuries, and antioxidant polyphenols, especially those from plant sources, exhibit antifibrosis properties. Such compounds can block activation of HSC and limit deposition of ECM and can be considered as new therapeutics for liver fibrosis.46 In continuation of this oxidative stress–driven regulation of HSC activation and HIF-1α described above, this pathway also has direct consequences for the role of HIF-1α in liver fibrosis, although it is essential to also consider the wider context of oxidant-dependent mechanisms that shape liver pathology. Fine-tuning between oxidative stress and antioxidant defence and HIF-1α activity modulation represents promising targets to the development of liver fibrosis therapies. Results showed that sauchinone, a lignan from Saurus chinensis, was able to inhibit HSC activation under oxidative stress and to block liver fibrogenesis. In LX2 cells, sauchinone pre-treatment also prevented the accumulation of HIF-1α, indicating its role in alleviating oxidative stress.47 Thus, oxidant stress drives liver fibrosis by activating hepatic stellate cells (HSCs), with HIF-1α acting as a key regulator of this process, including in the context of ferroptosis. Therapeutic interventions, such as the plant-derived compound sauchinone, can reduce fibrosis by inhibiting HSC activation and mitigating HIF-1α accumulation. Phytomedicines in HIF-1α inhibition and liver fibrosis Plants have essentially met the human demands, forming the basis of traditional healthcare systems like Ayurvedic, Unani and traditional Chinese medicines, which have ultimately contributed to modern medicines. Plant-derived pharmacological extracts owe their therapeutic efficacy to specific secondary metabolites and molecular classes synthesized for plant defense and environmental adaptation. Further studies indicate that herbal medicines from the Fabaceae, Asteraceae, and Lamiaceae families contain abundant phytochemicals, including flavonoids and alkaloids. These substances warrant thorough investigation due to the presence of active molecules including silymarin, plumbagin, and curcumin, which exhibit potential in the treatment of hepatic fibrosis, despite the absence of reliable antifibrotic therapies at present.48 In CCl4-treated mice, the HIF-1α expression was also reported to be elevated in liver tissue in six weeks. Administration of paeoniflorin tends to decrease the phosphorylation of mTOR (a product promoted by p-AKT) and also HIF-1α expression.49,50 Mitochondria-derived reactive oxygen species (ROS) are required for HIF-1α stabilisation and activation.51 “Oroxylin A, an O-methylated flavone found in medicinal plants, prevents alcohol-induced hepatic steatosis via the inhibition of HIF-1α.52 A report also focused on the involvement of vitamin C in decreasing HIF-1α protein expression and in lipid accumulation (Fig. 4).53 Resveratrol (RES) is a polyphenolic phytoalexin found in fruits such as raspberries and grapes and has been shown to have hepatoprotective effects in rats against liver injury induced by NDEA (Fig. 4). It restores Hepato-somatic Index, glycogen, SOD and ATPase activities, reduces AST, ALT, ALP and LPO levels, ameliorates liver architecture and collagen deposition.54,55 Although these phytochemicals differ structurally, most converge on a limited number of upstream mechanisms. These include the suppression of ROS generation, the inhibition of PI3K/Akt/mTOR signaling, the destabilization of HIF-1α, and the attenuation of HSC activation. This convergence suggests that HIF-1α functions as a common molecular hub through which diverse natural compounds exert antifibrotic activity. Overall, phytomedicines represent promising modulators of HIF signaling and may provide safer, multi-targeted therapeutic approaches for liver fibrosis management 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84. Role of HIF1A in ferroptosis and liver fibrosis. (A) Illustration of iron-induced oxidative damage and its role in liver fibrosis through HIF-1α and ferroptosis. Under hypoxic conditions, HIF-1α activation contributes to iron-mediated oxidative damage, with transferrin-bound iron interacting with transferrin receptors, leading to ferritin storage and lipid peroxidation via lipoxygenases. This lipid peroxidation drives ferroptosis, exacerbating liver fibrosis. (B) The figure also highlights therapeutic agents such as sorafenib, sauchinone, vitamin C, paeoniflorin, resveratrol, digoxin, oroxylin A, and curcumin, which target HIF-1α, ferroptosis, and oxidative stress to mitigate fibrosis progression Abbreviations: HIF-1α, hypoxia-inducible factor-1α; HIF1A, hypoxia-inducible factor-1α (gene encoding HIF-1α protein). Mechanisms of action of phytomedicine on HIF signaling Collectively, several phytomedicines have demonstrated the ability to modulate HIF-1α signaling and attenuate fibrogenic responses in experimental liver disease models. Phytomedicines such as paeoniflorin, procyanidin B2, oroxylin A, curcumol, and the Yiguanjian decoction demonstrate antifibrotic properties by inhibiting HIF-1α-dependent pathways, leading to diminished activation of hepatic stellate cells, angiogenesis, collagen accumulation, and inflammatory responses 49,56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84. Moreover, other phytochemicals examined in non-hepatic disease models have demonstrated significant HIF-1α inhibitory effects, indicating their potential for further assessment in liver fibrosis. A summary of these phytomedicines and their mechanisms of action is presented in Table 1, Table 2. Table 1Phytomedicines targeting liver disease via HIF-1α–dependent mechanism.Table 1No.Phytomedicines/Plant extractsMechanistic approachEffects on liver etiologyReferences1PaeoniflorinReduce phosphorylation of mTOR and the levels of HIF-1αAlleviates liver fibrosis by inhibiting HIF-1α through the mTOR-dependent pathway by reducing the expression of α-SMA and collagen III492Yiguanjian DecoctionInhibit HIF-1α/VEGF signaling pathwayAnti-angiogenic effects in CCl4induced liver fibrosis in mice563Fufang Biejia Ruangan TabletsDownregulate HIF-1α mRNA in liverAnti-liver fibrotic and cirrhotic effects574Green tea polyphenolsInhibit HIF-1α/Akt signaling pathwayImprove intra hepatic vascular proliferation, liver fibrosis, and portosystemic shunt in BDL rats575Astragalus membranaceusReduce HIF-1α in endothelial cells of HCCPromote vascular normalization in tumour-derived endothelial cells of HCC576Curcuma wenyujinReduce HIF-1α in endothelial cells of HCCPromote vascular normalization in tumour-derived endothelial cells of HCC577ResveratrolReduce the levels of HIF-1α by an underlying mechanismServe as an effective cancer therapy for the prevention of hepatic tumour growth588Procyanidin B2Downregulate the expression of VEGF-A, HIF-1α, α-SMA, col-I, and TGF-β1 of HSCs and promote its apoptosisReverse the progression of liver fibrosis in vitro and in vivo599Oroxylin A;LigustrazineGlucose metabolism regulation by oroxylin An under hypoxia;Activation of PPARγ that leads to transrepression of HIF-1α by SMRT-dependent mechanismContribute to its new anticancer mechanism;Prevention of hepatic fibrosis and cirrhosis60,6110CurcumolDecrease mRNA and protein expression of HIF-1α after VEGFA inductionInhibit angiogenesis of LSECs in liver fibrosis6211Saikosaponin-dReduce COX-2 expression via the p-STAT3/HIF-1α pathwayEffective against hepatocellular carcinoma6312BufalinInhibition of PI3K/AKT/mTOR pathway to reduce the expression of HIF-1αEffective against hepatocellular carcinoma6413DigoxinTarget HIF-1α transactivation via inhibiting PKM2Effective against non-alcoholic steatohepatitis6514MelittinPrevention of transcription and translation of HIF-1α, p-Akt, VEGF and MMP-2/9Effective against liver cancer6615SulforaphaneInhibition of STAT3/HIF-1α/VEGF signalingAnti-angiogenic effects against HCC6716ApigeninApigenin inhibited expression of HIF-1alpha and VEGF via the PI3K/AKT/p70S6K1 and HDM2/p53 pathwaysRole of apigenin is important for tumour angiogenesis and growth68 Phytomedicines targeting liver disease via HIF-1α–dependent mechanism. Table 2Phytochemicals that have been shown to affect HIF-1α signaling in diseases other than liver fibrosis.Table 2NOPlant extract/PhytomedicinesMechanistic approachEffects on other diseasesReferences1IsoquercetinSuppress NF-κB activation and reduce HIF-1α mRNA levelsPrevent osteoporosis caused by elevated levels of HIF-1α after menopause692AmpelopsinDecrease angiogenesis and cell proliferation via reducing the level of HIF-1α and VEGFR2Prevent cancer and disease involving the process of angiogenesis703FormonoetinDecrease angiogenesis and cell proliferation via reducing the level of HIF-1α and VEGFR2Prevent cervical cancer714LuteolinDecrease HIF-1α expressionPrevent abnormal glucolipid metabolism725ObtusifolinInhibit transcription and protein expression of HIF-1α and arrest the cells in the GI phasePrevent choroidal neovascularization736ShikoninPrevent nuclear translocation of NF-κB p65 and NF-κB activation by phosphorylation, also inhibit HIF-1α expressionPrevention of a variety of cancers747CrocinLowers the expression of HIF-1α and increases microRNA-320 expressionPrevent gastric cancer758FucoidanSuppressing HIF-1α/VEGF-C, which attenuates the PI3K/Akt/mTOR signaling pathwaysAnti-metastasis and anti-lymphangiogenesis activities769α-solanineDownregulate ERKI/2/HIF-1α and STAT-3 signaling pathwaysPrevention of pancreatic cancer7710Clematichinenoside ARReduce the expression of HIF-1α and suppress the level of hypoxia-induced TGF-β1Prevention of arthritis7811GinsenosideInhibit the expression of NF-κB and promote proteasomal degradation of HIF-1αPrevention of ovarian cancer7912CapsaicinReduce prostate-specific antigen and HIF-1α stabilisationPrevention of prostate cancer8013BerberinePromote HIF-1α degradation via a proteasomal proteolytic pathwayPrevention of gastric adenocarcinoma8114Triterpenoid saponinsDecrease VEGF protein levels in HIF-1α dependent mannerPrevention of ovarian cancer8215SulforaphaneBlock the translocation of HIF-1α to the nucleus and downregulate its expression and prevent cell proliferationPrevention of bladder cancer8316Isoliquiritin apiosideInhibit cell metastasis by preventing the activation of NF-κB and HIF-1α pathwayPrevention of several types of cancer84 Phytochemicals that have been shown to affect HIF-1α signaling in diseases other than liver fibrosis. Mechanism of action of HIF-1 inhibitors in liver fibrosis HIF-1 inhibitors are an important therapeutic approach for hepatic fibrosis induced by α-SMA.27 Several pharmacological approaches targeting HIF signaling have demonstrated antifibrotic effects in experimental liver disease models. The small-molecule inhibitor YC-1 has been reported to attenuate angiogenesis and fibrogenesis by suppressing the HIF-1α/STAT3 signaling pathways in liver fibrosis models. Similarly, the multikinase inhibitor sorafenib reduces hepatic stellate cell (HSC) activation and angiogenesis. It achieves this by downregulating the HIF-1α/SLC7A11 axis, which triggers HSC ferroptosis and ultimately attenuates fibrosis progression. These findings highlight HIF signaling as a promising therapeutic target; however, current evidence remains preclinical and requires further validation in clinical settings. These authors also presented a new therapeutic approach based on epigenetic inhibition of HIF-1α through DNMT, HDAC, and microRNA-targeted inhibitors.85 Epigenetic inhibitors and HIF-1α in liver fibrosis Epigenetic alterations in NAFLD offer important information on disease risk, disease progression, and prognosis, with fresh evidence suggesting they could also be important therapeutic targets and non-invasive biomarkers giving new insights regarding the handling and study of NAFLD. Additionally, sufficient HIF-2α activity in the liver drives development of hepatic steatosis and fibrogenesis.86 Inhibition of HIF-2α in the liver has been reported to attenuate NASH.87 In the advanced stage of NASH, the HIF-1α inhibitor YC-1 also inhibited liver fibrosis through SOCS1 and SOCS3-downregulation, crucial for inhibition of the NF-κB activation and STAT-3 phosphorylation.88 Studies have reported the development of 32-134D, a low-molecular-weight compound that effectively inhibits gene expression mediated by both HIF-1 and HIF-2 in hepatocellular carcinoma (HCC) cells.89 Collectively, epigenetic interventions regulate HIF signaling at multiple levels, including chromatin remodeling, transcriptional regulation, and post-transcriptional control. These findings indicate that targeting the epigenetic landscape may provide broader and potentially more durable suppression of profibrotic HIF signaling than direct HIF inhibition alone. Ferroptosis as a new therapeutic target of liver fibrosis Iron-induced oxidative stress plays a pivotal role in the evolution of liver fibrosis by enhancing lipid peroxidation and ferroptotic cell death. HIF-1α stabilisation and activation during hypoxia disrupts hepatic iron homeostasis, resulting in increased iron uptake via the transferrin receptor, intracellular iron accumulation and storage in ferritin. The excess ferrous iron catalyses the generation of reactive oxygen species (ROS) by Fenton reactions, leading to oxidative destruction of cellular membranes. The peroxidation of polyunsaturated fatty acids, catalysed by lipoxygenase, is a characteristic of ferroptosis that further accelerates this process. Ferroptotic cell death exacerbates liver cell damage and inflammatory signaling, leading to the activation of hepatic stellate cells and the deposition of extracellular matrix resulting in liver fibrogenesis. The data demonstrate the connection of hypoxia, HIF-1α signaling, iron-dependent oxidative damage and ferroptosis in liver fibrosis90 (Fig. 4). Ferroptosis is a unique iron-dependent cell death process characterized by extensive lipid peroxidation. Ferroptosis has been postulated as a potential new therapeutic target in liver fibrosis.61,71 In a healthy liver, SLC7A11 is normally expressed at very low levels, however during liver damage or stress (like NASH, iron overload, or toxin exposure), it is highly induced or upregulated to protect cells against oxidative damage and ferroptosis.90 The inhibition of HSC proliferation and promotion of apoptosis was further confirmed with the decrease of HIF-1α and SLC7A11 levels under Sorafenib.91 A serine protease inhibitor synthesized by hepatocytes through a hypoxia-dependent HIF-2α transcriptional mechanism, Serpin B3 is upregulated in response to the progression of chronic liver disease (CLD) and the development of hepatocellular carcinoma (HCC). Serpin B3 is a member of the serine-protease inhibitor (SERPIN) family originally described as squamous cell carcinoma antigen 1 and expressed at low levels in normal liver but strongly induced in chronically injured hepatocytes and in hepatocellular carcinoma cells. It has cytoprotective activity against oxidative stress and is inducible by hypoxia and hypoxia-inducible factor signaling in liver cells. It acts as a paracrine mediator that promotes hepatic stellate cell activation, inflammation and TGF-β–driven extracellular matrix deposition, with clinical links to fibrosis progression and HCC risk.92 The relationship between iron overload, lipid peroxidation, ferroptosis, and HIF-1α signaling is summarised in Fig. 4. This figure also includes the pharmacological and phytochemical modulators capable of attenuating HIF-driven ferroptotic injury. Inhibition of HSCs activation and neutralization of VEGF Antibodies that neutralise the VEGF receptor (VEGFR) have also been explored. These receptors are the locks on the surface of cells that VEGF can turn to ignite blood vessel growth. Anti-VEGFR1 and anti-VEGFR2 are two types of antibodies that have been investigated.93 In this regard, it has been proven that the anti-VEGFR2 antibody had a greater effect than the anti-VEGFR1 antibody on its own. Drugs that inhibit multiple receptor tyrosine kinases involve blocking signals from multiple receptors, such as vascular endothelial growth factor receptors (VEGFRs) and PDGFR-β.94 These signals are chemical messengers that instruct cells to grow and divide. Sorafenib and sunitinib relieve liver fibrosis by blocking the path of these messengers. Sunitinib can also contribute to the reduction of liver fibrosis by decreasing the inflammatory response, inhibiting the activation of HSCs, and angiogenesis.95 Celecoxib, a cyclooxygenase-2 inhibitor, has been confirmed through studies that can reduce liver fibrosis similarly to sorafenib.96 Matrix metalloproteinases, notably MMP-2 and MT1-MMP/MMP-14, drive scar breakdown by degrading basement-membrane and interstitial matrix or by activating other proteases, while TIMP-1/2 inhibit this process. Documented animal and interventional studies link increased MMP activity and reduced TIMPs to fibrosis regression.97 EPCs injected into a model of liver fibrosis in rat were shown as a promising approach. Activated stellate cells are involved in the remodeling of the damaged liver tissue by promoting ECM degradation mediated by MMPs and by other proteases.98 The investigation of bioactive food components and natural products, exemplified by TNP-470, presents promising modalities for liver fibrosis prevention and treatment.3 This is due to the antioxidant, anti-inflammatory effects of various compounds such as astaxanthin and curcumin as well as the ability to revert activated hepatic stellate cells back to a quiescent state.99 HIF-1α upregulation rescues acetaminophen-induced necrosis and protects against alcohol-induced fatty liver disease, while PHD inhibitors also stabilise HIFs and counteract liver disease in even high-fat diet mice. HIF-P4H-2 regulates fructose metabolism and heat production, and VEGF blockade in HCC prevents hypoxia-induced HIF-1α and overcomes drug resistance. Clinical trials have demonstrated that agents targeting HIF, including EZN-2968 and ethyl 3,4-dihydroxybenzoate, are a potential therapeutic strategy for HCC and IR-induced liver injury as they upregulate HIF-1α and heme oxygenase 1.100 As discussed in Section 3.2, VEGF-mediated angiogenesis is a major driver of liver fibrosis. Therapeutic approaches targeting VEGF signaling, including anti-VEGFR antibodies and multi-kinase inhibitors, have therefore been explored. Furthermore, the pharmacological inhibition of HIF signaling demonstrates significant antifibrotic potential in preclinical studies, although further clinical validation remains necessary. HIF-dependent cell signaling pathways in the progression of liver fibrosis Wang and co-workers investigated how HIF-1α and MAPK were jointly regulated during hypoxic stimulation of hepatic stellate cell (HSC) activation. HIF-1α has been suppressed by RNA interference, resulting in tumour growth inhibition, and HIF-1α inhibition via rapamycin was shown to be critical for inhibition of HCC tumorigenesis.101 Silibinin demonstrated anti-tumour activity through HIF-1α signaling inhibition by mTOR phosphorylation.102 Zhao and coworkers showed that the ERK/HIF-1α signaling pathway may participate in the progression of liver fibrosis.49 Wang et al. have highlighted the important role of miR-98 in HSC activation and the progression of liver fibrosis. They demonstrated that miR-98 downregulated α-SMA, collagen-I, TIMP-1, HLF, HIF-1α, TGF-β and Smad 2/3 activation in the liver tissues of CCl4, BDL and HFD-treated mouse models. Further, the results indicate that miR-98 governs HSC activation suggesting that miR-98 may serve as a promising target for liver fibrosis therapy. RAW264.7 cells are polarised by various proinflammatory cytokines, including IL-1α, IL-1β, IL-6, IL-12, and TNF-α, to produce M1 macrophages. These cytokines further promote liver injury by stimulating inflammation and activating hepatic stellate cells (HSCs), resulting in liver fibrosis. M2 macrophages are anti-inflammatory and stimulated by cytokines such as IL-10, CCL1, and VEGF. These cytokines contribute to ameliorate the inflammatory response and facilitate tissue repair, hence offering a protective role against liver injury and fibrosis.103 Higher NF-κB/HIF-1α pathway activity in liver tissues injured by CCl4 promotes both inflammation and fibrosis. Paeoniflorin treatment lowers the levels of NF-κB and HIF-1α proteins associated with these adverse effects. NF-κB is activated through a series of steps that enable it to translocate to the nucleus of the cell and induce the expression of the genes responsible for inflammation. Hypoxia, can increase HIF-1α levels to promote NF-κB activity while YC-1, an HIF-1α antagonist, could diminish the NF-κB/HIF-1α axis.88 Role of MAPK, mTOR, and other pathways in HIF signaling MAPK and mTOR were the major hypoxia-stimulated pathways regulating HIF-1α activity. These pathways inhibit HIF-1α ubiquitination and facilitate its nuclear translocation. HIF-1α then induces the expression of downstream cytokines, such as CTGF, which activate HSCs.49 Hypoxia-induced MAPK activation is necessary for HIF-2α activity and thus can be a target for inhibiting HIF-2α-mediated hepatic fibrosis progression. Upregulated HIF-1α drives the expression of target genes like LOX, Snail 1, and Twist, highlighting its epithelial-mesenchymal transition (EMT)-promoting role and possible link to fibrosis.13 The up-regulation of HIF-1α promotes extracellular matrix (ECM) synthesis and drives fibrogenesis. Studies demonstrate that hypoxia-induced HIF-1α activity activates hepatic stellate cells (HSCs) via downstream cascades such as the PI3K/AKT signaling pathway.104 This pathway activation subsequently inhibits PPAR-γ expression, ultimately resulting in HSC activation.105 Another study utilizing hepatic stellate cells (HSCs) and Kupffer cells demonstrated a key role for Toll-like receptor 4 (TLR4) signaling in liver fibrosis. In this mechanism, augmented lipopolysaccharide (LPS) levels, often triggered by increased gut permeability or hypoxic conditions, activate TLR4 on HSCs and macrophages, promoting pro-inflammatory pathways that drive fibrogenesis.106 Moreover, hypoxia has been found to up-regulate markers of fibroblasts, including α-SMA and vimentin, stimulating EMT and liver fibrosis.45 HIF-1α most significantly activates the transcription of lysyl oxidase (LOX), which is known to induce epithelial-mesenchymal transition (EMT) in response to hypoxic conditions.107 The involvement of receptor tyrosine kinases (RTKs), especially in relation to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), has been explored in multiple studies.108 HIF-1α knockdown was linked to decreased expression of collagen 1A1, collagen 3A1, and Rho-associated protein kinase 1 (ROCK1), which are key players in HSC activation under hypoxic conditions.109 In the liver-specific PTEN-deficient mice, NASH with fibrosis was noted with the elevated expression of PPAR-γ and SREBP-1C, which are important factors in lipogenesis and progression of fibrosis.110 Metformin has been reported to attenuate pIVCL-induced liver fibrosis by decreasing liver congestion; downregulating collagen, fibronectin, α-SMA, HIF-1α, and VEGF; and inhibiting hepatic stellate cell (HSC) proliferation, migration, and activation via the mTOR/HIF-1α signaling pathway.111 Activation of the hedgehog pathway leads to the production of hypoxia-inducible factor-1α (HIF-1α), which further enhances the Warburg effect in HSCs. Moreover, TGF-β1 promotes aerobic glycolysis through the Smad, p38 MAPK, and PI3K/AKT signaling pathways.112,113 Hedgehog (Hh) activation in hepatic stellate cells (HSCs) increases HIF-1α protein/activity and drives an aerobic glycolytic program (HK2, GLUTs, PFK2, LDH-A, PKM2). Pharmacologic and genetic perturbations in HSC culture and rodent fibrosis models provide mechanistic and functional evidence. LDH-A coupled with HIF-1α promotes hyperexpression of gene transcription to sustain the Warburg effect and liver fibrosis. Moreover, the Wnt/β-Catenin pathway upregulates LDH-A activity, and the inhibition of LDH-A can also attenuate liver fibrosis.114 Despite diverse etiologies, profibrotic pathways ultimately converge on the hypoxia-inducible factor (HIF) signaling axis, establishing it as a key integrative node in hepatic fibrogenesis. Specifically, upstream signaling cascades—including TGF-β/Smad, PI3K/Akt, NF-κB, and VEGF, all contribute to HIF-dependent activation of hepatic stellate cells. This unified regulatory hub drives extracellular matrix (ECM) deposition, inflammatory cytokine release, and angiogenesis, culminating in progressive hepatic fibrosis. VHL overexpression and liver fibrosis pVHL acts as an E3 ubiquitin ligase in an oxygen-dependent manner and acts to degrade HIF-α through the activity of the PHD family of prolyl hydroxylases. When O2 is low, or pVHL is mutated (or absent) then HIF-α accumulates, making HIF-α a main driver of transcription and thus associated with progression of the tumour. pVHL is an important tumour suppressor gene that controls the hypoxia-inducible factors HIF-1α and HIF-2α, both of which are associated with tumour-promoting gene expression, emphasising its importance in cancer biology.108 Analyses have revealed that pVHL regulates the stability of Smad 3 in epithelial cells and targets it for proteasomal degradation, thereby modulating transcriptional responses to TGF-β-Smad3 canonical signaling.115 This evidence of multiple roles of pVHL highlights the relevance of pVHL in tumour suppressions as well as justifies pVHL's potential application for treating cancer and fibrosis.116 Thus, beyond HIF degradation, pVHL also modulates the TGF-β/Smad axis, further contributing to its antifibrotic effects. Thereafter, various fibrotic markers, VHL, HIF-1α, and HIF-2α must be examined. An increase in fibrotic marker, smooth muscle actin (SMA) was demonstrated in mice with disrupted VHL (and subsequently increased with HIF-1α and HIF-2α).31 VHL expression in the liver sections of fibrosis patients with a higher level of HIF-1α and HIF-2α was detected at a lower level. In experimental models of chronic liver diseases, the following effects were observed upon overexpression of VHL-namely; suppression of fibrogenic genes, blocking activation of mouse HSCs, liver fibrosis inhibition, suppression of liver inflammation and, induction of apoptosis. The focus had been more on the upregulation of VHL for fibrosis prevention because it was demonstrated to be more effective than the silencing of HIF-1α and HIF-2α. Wang et al. for the first time, demonstrated that the expression of the VHL is perilously regulated in cholestatic liver cirrhotic livers as compared to healthy livers. Overexpression of VHL inhibits the accumulation and expression of HIF-1α and HIF-2α and also ameliorates the progression of liver fibrosis.117 The study by Qu et al. demonstrated increased expression of genes that encode proteins necessary for collagen synthesis (α-SMA, procollagen lysine, 2-oxoglutarate-5-dioxygenase 2 [PLOD-2] and transglutaminase-2 [TGM2]) in VHL knockout mice. Notably, this upregulation was not seen in VHL-HIF-2α double knockout mice, highlighting the role of HIF-2α in driving the progression of liver fibrosis.31 Overall, restoration or enhancement of VHL function represents a promising strategy for suppressing HIF activity and attenuating fibrosis progression. Discussion The present document integrates current evidence regarding the central role of hypoxia-inducible factors, particularly HIF-1α, in the development and progression of liver fibrosis. Chronic liver injury leads to the establishment of a hypoxic microenvironment, which in turn triggers the activation of hepatic stellate cells (HSCs), extracellular matrix accumulation, angiogenesis, and inflammation. HIF-1α serves as a primary molecular mediator connecting hypoxia to these fibrogenic events. Current research indicates that HIF signaling is tightly coordinated with essential profibrotic pathways, including TGF-β/Smad, NF-κB, mTOR, MAPK, and PI3K/AKT. HIF-1α interacts with these pathways to upregulate collagen formation, α-SMA expression, cytokine production, and vascular remodeling. Moreover, emerging evidence highlights that HIF-mediated metabolic reprogramming and ferroptosis contribute to the prolonged activation of stellate cells and fibrogenesis. The role of HIF signaling is highly context-dependent. While HIF-1α promotes fibrogenesis in activated HSCs, it may also exert protective effects in hepatocytes and endothelial cells under certain circumstances. Furthermore, recent findings reveal that HIF-1α and HIF-2α possess unique, stage-specific functions in the development of steatohepatitis, severe fibrosis, and the progression to cirrhosis and hepatocellular carcinoma. Natural bioactive substances—such as flavonoids, coumarins, quinones, and phenolic derivatives—are increasingly recognized for their hepatoprotective benefits, acting via antioxidant and anti-inflammatory mechanisms.118 Pharmacological HIF inhibitors, VHL overexpression techniques, epigenetic modifiers, and phytochemicals (like resveratrol and curcumin) have exhibited antifibrotic characteristics in preclinical animal models. Because much of the current knowledge is restricted to in-vitro research and animal models, considerable caution is required when translating these experimental therapies into clinical applications. However, translating HIF-targeted treatments for liver fibrosis from preclinical studies to the clinic presents several challenges. The HIF signaling pathway is highly complex, featuring cell-specific and context-dependent actions that regulate fibrogenesis, angiogenesis, inflammation, and tissue repair. Determining the optimal HIF isoform and cellular target remains difficult, as blocking a single HIF route may be inadequate due to compensatory pro-fibrotic signaling networks and redundant hypoxia-responsive pathways. Furthermore, the global suppression of HIF signaling may cause off-target effects, given that HIFs regulate critical physiological processes such as metabolism, angiogenesis, and immunological responses across diverse hepatic and extrahepatic cell types.119,120 These hurdles underscore the need for a deeper understanding of HIF isoform-specific actions and the development of cell-selective treatment methods. Another key challenge is the limited translational applicability of existing preclinical models. Experimental models often fail to adequately recreate the chronic progression, etiological diversity, and vascular remodeling characteristics of human liver fibrosis, which reduces the predictive value of preclinical efficacy findings. Additionally, the efficient and selective delivery of therapeutic drugs to fibrogenic cells—especially activated hepatic stellate cells (HSCs)—is a prerequisite for successful clinical translation. While the proof-of-concept for HSC-specific delivery has been demonstrated using targeted techniques such as vitamin A-adorned micellar systems, challenges regarding biodistribution, manufacturing, scalability, and long-term safety remain to be addressed 121, 122, 123. Finally, the complexity of clinical development is compounded by a lack of validated biomarkers to monitor HIF activity and treatment response, substantial patient variability, and difficulties in selecting suitable clinical endpoints for anti-fibrotic trials.124 Future advances will rely on isoform-specific regulation, tailored drug delivery systems, biomarker-guided patient categorization, and well-designed clinical studies to determine the safety and efficacy of HIF-directed therapeutics for liver fibrosis. However, clinical assessment of HIF-targeted treatments for liver fibrosis remains sparse, and no HIF inhibitor has been approved by regulatory agencies for this indication to date. This gap between promising preclinical outcomes and successful clinical translation is primarily driven by disease heterogeneity, inadequate patient classification, a lack of validated pharmacodynamic biomarkers, and the inherent difficulty of demonstrating antifibrotic efficacy within manageable trial durations. Conclusion and future plans In this review, we have concentrated on HIF-1α, a crucial regulator of hypoxia-induced liver fibrosis. HIF signaling mediates a complex interplay between angiogenesis, inflammation, metabolism, and extracellular matrix remodeling that heavily drives the pathogenesis of chronic liver injury. Novel antifibrotic approaches, such as targeting the VHL-HIF pathway, modulating downstream signaling, and harnessing plant-derived bioactive molecules, show promising preclinical data. Future studies should focus on the development of cell-type-specific approaches that specifically target activated hepatic stellate cells while sparing beneficial hypoxia responses in other liver cell types. Furthermore, studies explicitly separating the roles of HIF-1α and HIF-2α in different phases of fibrosis are especially needed. Advances in targeted drug delivery, RNA therapeutics, proteolysis targeting chimera-mediated degradation, and epigenetics may also increase therapeutic specificity.125 Additionally, the use of organoid cultures, humanized mouse models, and multi-omics approaches would significantly boost the translational value of such investigations. Well-designed clinical studies are needed to assess the safety and efficacy of HIF-targeting therapy and their long-term consequences. In summary, therapeutic modulation of hypoxia signaling looks promising for chronic liver diseases, despite numerous difficulties. Further research and development will be necessary to translate promising preclinical data into effective clinical therapies. CRediT authorship contribution statement Yasha Taimuri: Writing – original draft, Data curation, Conceptualization, Validation, Visualization. Riaz Ahmad: Writing – review & editing, Supervision, Conceptualization, Project administration, Resources. Informed consent Not applicable. Organ donation Not applicable. Animal treatment Not applicable. Data availability statement No data was generated in this study. Ethics statement Not applicable. Declaration of generative AI and AI-assisted technologies in the writing process During the preparation of this manuscript the authors used online QuillBot (version: 4.102.1, Learneo, Inc. Chicago), Grammarly (Grammarly Inc., USA) in order to improve the language of the manuscript. The authors reviewed and edited the content as needed and took full responsibility for the published article. Funding None. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgement The authors acknowledge the support from the Department of Zoology, Aligarh Muslim University, for providing literature search and other infrastructural facilities during the preparation of this manuscript. References Associated Data Data Availability Statement No data was generated in this study.